{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:20:12Z","timestamp":1790216412779,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["P01 AI098681-07"],"award-info":[{"award-number":["P01 AI098681-07"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["1R01 AI158488-01"],"award-info":[{"award-number":["1R01 AI158488-01"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016394","name":"Harvard Medical School Ludwig Center at Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["1K08DK114563-01"],"award-info":[{"award-number":["1K08DK114563-01"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1K08DK114563-01"],"award-info":[{"award-number":["1K08DK114563-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 AI098681-07"],"award-info":[{"award-number":["P01 AI098681-07"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["F31 CA235898-01"],"award-info":[{"award-number":["F31 CA235898-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000875","name":"PEW Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.celrep.2023.112219","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T17:22:22Z","timestamp":1678123342000},"page":"112219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["IFN\u03b3 is a central node of cancer immune equilibrium"],"prefix":"10.1016","volume":"42","author":[{"given":"Michael J.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney T.","family":"Stump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakeeb","family":"Kureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lenehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lestat R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Knipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2023.112219_bib1","first-page":"55","article-title":"Cancer immunotherapy: beyond checkpoint blockade","volume":"3","author":"Dougan","year":"2019","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.celrep.2023.112219_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2023.112219_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.112219_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2023.112219_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In\u00a0vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.112219_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.112219_bib8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T\u00a0cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.celrep.2023.112219_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib11","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2023.112219_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-\u03b3 drives Treg fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1172\/JCI33522","article-title":"IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers","volume":"118","author":"Zhang","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2023.112219_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.112219_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib17","doi-asserted-by":"crossref","first-page":"17343","DOI":"10.1073\/pnas.0605102103","article-title":"Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells","volume":"103","author":"Sato","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.112219_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20030162","article-title":"Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells","volume":"198","author":"Lund","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.0308057100","article-title":"Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis","volume":"101","author":"Kurt-jones","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.112219_bib20","doi-asserted-by":"crossref","first-page":"13315","DOI":"10.1128\/JVI.01167-07","article-title":"Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems","volume":"81","author":"Rasmussen","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2023.112219_bib21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.celrep.2023.112219_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002371-199308000-00012","article-title":"Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer","volume":"14","author":"Zeh","year":"1993","journal-title":"J. Immunother. Emphas. Tumor Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-018-0044-5","article-title":"Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy","volume":"26","author":"Mukhopadhyay","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.celrep.2023.112219_bib26","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ni.1947","article-title":"IL-12 initiates tumor rejection via lymphoid tissue\u2013inducer cells bearing the natural cytotoxicity receptor NKp46","volume":"11","author":"Eisenring","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.celrep.2019.08.095","article-title":"Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment","volume":"29","author":"Mills","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2023.112219_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007209","article-title":"A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors","volume":"14","author":"Leoni","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2023.112219_bib29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.112219_bib30","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.112219_bib31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1089\/hum.1996.7.16-1995","article-title":"Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12","volume":"7","author":"Bramson","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.celrep.2023.112219_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/mt.2012.56","article-title":"Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12","volume":"20","author":"Quetglas","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.celrep.2023.112219_bib33","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1158\/1078-0432.CCR-17-1717","article-title":"Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models","volume":"24","author":"Saha","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2023.112219_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.gt.3300834","article-title":"Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model","volume":"6","author":"Nasu","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.celrep.2023.112219_bib35","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","article-title":"In situ cancer vaccination: an IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor activity","volume":"160","author":"Toda","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib36","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1021\/mp300602j","article-title":"Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12","volume":"10","author":"Cao","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.celrep.2023.112219_bib37","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12 \u2013 associated toxicity and interferon-g production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2023.112219_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.celrep.2023.112219_bib39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib40","doi-asserted-by":"crossref","first-page":"101473","DOI":"10.1016\/j.smim.2021.101473","article-title":"Checkpoint blockade toxicities: insights into autoimmunity and treatment","volume":"52","author":"Walsh","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib41","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1016\/j.vaccine.2009.03.003","article-title":"Genetic engineering of a modified herpes simplex virus 1 vaccine vector","volume":"27","author":"Liu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2023.112219_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.virol.2006.08.015","article-title":"Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector","volume":"357","author":"Watanabe","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.celrep.2023.112219_bib43","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/JVI.72.4.3307-3320.1998","article-title":"Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins","volume":"72","author":"Samaniego","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2023.112219_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fimmu.2019.00002","article-title":"Generation of an oncolytic herpes simplex virus 1 expressing human MelanA","volume":"10","author":"Boscheinen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib45","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1158\/1078-0432.CCR-17-2954","article-title":"Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma","volume":"24","author":"Nakashima","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2023.112219_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/mthe.2000.0240","article-title":"Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1","volume":"3","author":"Miller","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.celrep.2023.112219_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/eji.1830250133","article-title":"Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist","volume":"25","author":"Gillessen","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt0197-35","article-title":"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo","volume":"15","author":"Lieschke","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.celrep.2023.112219_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4049\/jimmunol.154.1.116","article-title":"Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity","volume":"154","author":"Ling","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/imm.12509","article-title":"Combined cytotoxic activity of an infectious , but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. Immunology","volume":"146","author":"Thomann","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.celrep.2023.112219_bib51","doi-asserted-by":"crossref","first-page":"E3008","DOI":"10.1073\/pnas.1211302109","article-title":"Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein","volume":"109","author":"Orzalli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.112219_bib52","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/jvi.76.5.2180-2191.2002","article-title":"Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection","volume":"76","author":"Eidson","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2023.112219_bib53","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3245::AID-IMMU3245>3.0.CO;2-X","article-title":"Inhibition of dendritic cell maturation by herpes simplex virus","volume":"29","author":"Salio","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2023.112219_bib55","doi-asserted-by":"crossref","first-page":"210245","DOI":"10.1098\/rsob.210245","article-title":"Radiation combines with immune checkpoint blockade to enhance T\u00a0cell priming in a murine model of poorly immunogenic pancreatic cancer","volume":"11","author":"Stump","year":"2021","journal-title":"Open Biol."},{"key":"10.1016\/j.celrep.2023.112219_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/2326-6066.CIR-13-0047","article-title":"Transnuclear TRP1-specific CD8 T\u00a0cells with high or low affinity TCRs show equivalent antitumor activity","volume":"1","author":"Dougan","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2023.112219_bib58","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/eji.200939842","article-title":"T-bet, a Th1 transcription factor regulates the expression of Tim-3","volume":"40","author":"Anderson","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib59","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.4049\/jimmunol.174.12.7732","article-title":"The functional heterogeneity of type 1 effector T\u00a0cells in response to infection is related to the potential for IFN-gamma production","volume":"174","author":"Mayer","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1084\/jem.20030584","article-title":"\u03b3\u03b4 T\u00a0cells provide an early source of interferon \u03b3 in tumor immunity","volume":"198","author":"Gao","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib62","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1126\/scitranslmed.abf5058","article-title":"cIAP1\/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes","volume":"13","author":"Roehle","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib63","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","article-title":"Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state","volume":"72","author":"Teng","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.112219_bib64","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12079-018-0486-y","article-title":"Comprehensive network map of interferon gamma signaling","volume":"12","author":"Bhat","year":"2018","journal-title":"J.\u00a0Cell Commun. Signal."},{"key":"10.1016\/j.celrep.2023.112219_bib65","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1996.tb52664.x","article-title":"A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12","volume":"795","author":"Angiolillo","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.celrep.2023.112219_bib68","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fimmu.2015.00486","article-title":"Ontogeny of tissue-resident macrophages","volume":"6","author":"Hoeffel","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib69","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T\u00a0cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2893.2010.01335.x","article-title":"Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users","volume":"18","author":"Flynn","year":"2011","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.celrep.2023.112219_bib71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.celrep.2023.112219_bib72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2023.112219_bib73","doi-asserted-by":"crossref","first-page":"735643","DOI":"10.3389\/fimmu.2021.735643","article-title":"Tissue-resident-memory CD8+ T\u00a0cells bridge innate immune responses in neighboring epithelial cells to control human genital herpes","volume":"12","author":"Peng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2023.112219_bib74","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1097\/QAD.0b013e328359b7e0","article-title":"Breast milk cellular HIV-specific interferon \u03b3 responses are associated with protection from peripartum HIV transmission","volume":"26","author":"Lohman-Payne","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.celrep.2023.112219_bib75","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/QAD.0b013e3283367836","article-title":"Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression","volume":"24","author":"Roberts","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.celrep.2023.112219_bib76","article-title":"CRISPR-Cas9 expressed in stably transduced cell lines promotes recombination and selects for herpes simplex virus recombinants","volume":"3","author":"Oh","year":"2022","journal-title":"Curr. Res. Virol. Sci."},{"key":"10.1016\/j.celrep.2023.112219_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00057-18","article-title":"Mechanisms of host IFI16, PML, and daxx protein restriction of herpes simplex virus 1 replication","volume":"92","author":"Merkl","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.celrep.2023.112219_bib77","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.celrep.2023.112219_bib78","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2023.112219_bib79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1261\/rna.2192803","article-title":"Lentivirus-delivered stable gene silencing by RNAi in primary cells","volume":"9","author":"Stewart","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.celrep.2023.112219_bib80","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2023.112219_bib82","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41467-018-05083-x","article-title":"Detection and removal of barcode swapping in single-cell RNA-seq data","volume":"9","author":"Griffiths","year":"2018","journal-title":"Nat Commun."},{"key":"10.1016\/j.celrep.2023.112219_bib83","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.112219_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.celrep.2023.112219_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2023.112219_bib87","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","article-title":"Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences","volume":"4","author":"Soneson","year":"2015","journal-title":"F1000Res."},{"key":"10.1016\/j.celrep.2023.112219_bib92","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.celrep.2023.112219_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2023.112219_bib90","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2023.112219_bib81","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/2326-6066.CIR-18-0348","article-title":"Altered binding of tumor antigenic peptides to MHC class I affects CD8+ T\u00a0cell-effector responses","volume":"6","author":"Clancy-Thompson","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2023.112219_bib85","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2326-6066.CIR-17-0495","article-title":"Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs","volume":"6","author":"Dougan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.celrep.2023.112219_bib88","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124723002309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124723002309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:54:11Z","timestamp":1778842451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124723002309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2211124723002309"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2023.112219","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN\u03b3 is a central node of cancer immune equilibrium","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2023.112219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"112219"}}